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Newsletter - December 2016 
 
Revolution and counter-revolution: the state of substance misuse 
treatment in the UK  
 
Aldous Huxley - that fine author and “drug misuser” - once said: “That men do not learn very much 
from the lessons of history is the most important of all the lessons from history.”  And so in 
addressing what I think the future of drug treatment might look like, I will start with some brief 
reflections on where we came from, because there-in lie lessons that it seems we have yet to learn. 
 
Throughout my five years of undergraduate training four decades ago, I never received a single 
lecture on chemical dependency – sadly that seems to be still true for many medical schools to this 
day. Addiction treatment in the 1970s was in the hands of a handful of psychiatrists scattered over 
the UK, who had enormous waiting lists as a consequence. If someone seeking addiction treatment 
was lucky enough to survive the wait to see one, “treatment” was almost universally time limited and 
abstinence focused – and if you relapsed, well, it was your fault, you had had your chance after all.  
 
The 1980s saw the emergence of the HIV (and HCV) epidemics and by the end of that decade the 
National Treatment Outcome Research Study (NTORS) had produced its earth shattering statement 
that if you “spend £1 on treatment, that saves £3 elsewhere”... and the treatment they evaluated 
was predominantly opioid substitution treatment (OST) maintenance prescribing. All of a sudden 
politicians became concerned with harm reduction treatment provision, and come 2001, the 
National Treatment Agency for Substance Misuse (NTA) was created to oversee the creation and 
quality monitoring of treatment services, and to harmonise what was at the time a “postcode lottery”. 
The services created were initially delivered through NHS community psychiatric services as GPs 
were still actively discouraged from involving themselves in addiction treatment. But by the mid- 
1990s the annual RCGP conference on managing drug and alcohol problems in primary care had 
already started, and was subsequently followed by the creation of the RCGP Certificate in the 
Management of Drug Misuse and a tidal wave of primary care involvement followed after that. 
 
What followed over the ensuing decade can only be described as a revolution – 200,000 heroin 
users in treatment annually, 11,000 GPs completing the RCGP Certificate and getting involved in 
community treatment, and access to treatment becoming almost immediate at most points in the 
country. Premature deaths were being averted, disease transmission reduced, crimes and 
imprisonments fell and families stayed together. However the vast gains of so much treatment came 
at considerable cost, and by the middle of the “Noughties” competitive tendering by commissioners 
led to more efficient Third Sector companies being handed a greater and greater proportion of 
community treatment, hitherto delivered by the NHS.  
 
The 2010 Coalition government saw a seismic shift in political bias toward abstinence-oriented 
treatment, the Health and Social Care Act of 2012 saw the disbanding of the NTA, and the funding 
of drug treatment delegated to local authorities. And soon after that followed austerity, savage cuts 
in local authority budgets, and most recently “Brexit”. 
 
So, in getting to where we are today, drug treatment over the past few decades in the UK went from 
a tiny number of time-limited abstinence-oriented specialist services of varying quality and quantity, 
through a boom of effective service delivery across the majority of the UK; with addiction medicine 
legitimised, mainstreamed into primary care, and treatment demonstrated to be both effective and 
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But almost as quickly as this revolution happened, a counter-revolution is already well under way: 
 
• Erosion of specialism: Addiction as a specialism is being extinguished; the failure of 
education mechanisms to adapt to the new landscape of treatment provision has indirectly 
led to less than half the number of Specialist Registrars training in addiction medicine today 
than there were just a few years ago – where will tomorrow’s research and experts come 
from? Where will the Mental Health Trusts get expertise from for all their general psychiatry 
patients with co-morbid addictive problems? 
 
• The politically arbitrary prejudice that favours abstinence: We need to be honest here – 
whilst we were complacently congratulating ourselves for all of the harm that maintenance 
prescribing was undoubtedly reducing, it did come at the cost of ambition for the patient to 
regain his or her independence. There is no doubt that the misnamed “recovery agenda” has 
encouraged more well-resourced and resilient people to leave treatment and gain 
independence sooner than they would have done without the leverage. But idealistic zeal 
needs to be tempered because there is a spectrum of “recovery capital” and the recovery 
trajectory of many will be slow, and fragile. 
 
• Funding cuts: Despite the overwhelming evidence of addiction treatment cost-effectiveness 
from numerous Returns on Social Investment studies which confirm that at the very least it 
pays for itself, there is a Russian Roulette of commissioning out there. Every commissioning 
cycle is an empirical experiment in cost cutting – how cheap can we go before the sky falls 
in? No one knows – but the bear pit of competitive tendering compels all involved to put 
hope before expectation. And with competing calls on County Halls’ diminishing budgets 
from children that need safeguarding, frail elderly who need care and even holes in the road 
that need to be filled, drug addiction treatment is a soft target for the cuts. 
 
• And the recommissioning cycles cause widespread disillusionment and chaos – it is utterly 
extraordinary that the complex care of hundreds - or sometimes thousands of vulnerable 
people - can be just torn up overnight as offices and phone numbers change, staff melt 
away, thousands of potentially life-threatening CD prescriptions taken from one computer 
system and put on another, and, vitally, the critical therapeutic relationships between patient 
and worker disrupted on a grand scale – and all this is possible because of some arcane 
European regulation which was designed to obtain best value for County Halls’ stationery 
supplies, or waste collections – but not for complex medical services. That major disasters 
have thus far been averted does credit to all involved, but that doesn’t make it right. 
 
Now, with drug related deaths at an all-time high, alcohol consumption at an all-time high, and child 
safeguarding and sexual abuse awareness also at an all-time high, it might be assumed that 
addiction services would be further invested in – but no, they could not be under more threat; 
indeed all the lessons that we have learned and all of the treatment gains over recent decades 
could be reversed – the country (well, England and Wales anyway) seems hell-bent on returning to 
a landscape of almost no specialists and time limited abstinence-oriented services according to 
local whim. 
 
So is this cyclical, and are we are at the bottom of a cycle? Or is this more linear and headed we 
know not where? Will an upswing of investment depend on another catastrophe like AIDS – some 
new BBV, or contagion from drug injectors to the wider population to create panic and proper 
funding? Or a new drug epidemic, as we might be beginning to see of Fentanyl? Or a novel 
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Or are we simply going to bottom out at a level of funding that reflects the wider population’s 
disinterest and prejudice about the worth of treating “drug addicts”? What must happen in my view 
is: 
 
o Reverse some of the harms of the Health and Social Care Act. There must be joint 
commissioning of addiction services between Clinical Commissioning Groups and Local 
Authorities - or put them back into the NHS – it is bonkers to dislocate cause from effect: CCGs 
pick up all of the costs of addiction in A&E departments, liver units etc.– so they should have an 
investment in treating the cause of the problem. 
 
o Argue for minimum standards and funding in treatment services – the postcode lottery is 
unacceptable anyway, but when left to the whims of local authorities and subject to far more 
prejudice than any other branch of medicine, it must be protected. We wouldn’t tolerate such 
arbitrary funding of cancer services, so why should it be acceptable in addiction services? 
o It is not too late (but it nearly is) to compel RCPsych and Health Education England to overcome 
their inertia and work with the Third Sector to safeguard the training of the future specialist... we 
must argue for mandatory funding of training in all commissions to continue the training of 
doctors, nurses and psychologists in addiction medicine, as well as the competencies of generic 
staff in quasi-medical roles. 
o Stop the nonsense of pointless recommissioning – of course taxpayers’ money should be 
spent well and funders should have the right to get rid of bad and/or inefficient services …but 
recommissioning has become a habit; even high performing services are being dismantled and 
good services being disrupted. Recommissioning needs to justify its very considerable costs.  
Because it: 
• demoralises staff – the best ones leave 
• guarantees far worse performance for 18 months 
• costs a lot of money 
• rips up therapeutic relationships 
 
Services need evolution not revolution... and if this really is a European piece of legislation, maybe 
Brexit might help! 
 
There is one thing that has happened over the past 40 years which I do not believe will be reversed, 
which is the invaluable involvement of general practice: GPs are the experts in chronic relapsing 
conditions; addiction ravages families, they are the experts in family medicine. And as addiction 
stems from damage to mental, social and physical health, so GPs are trained to address these 
same three dimensions of health. It is exactly right that general practice should take a major part in 
community treatment and every year our annual conference renews my faith that despite all of the 
pressures on primary care, there remain a lot of very good people at the heart of addiction 
treatment.  
 
People who use drugs fascinate us because they pose unique challenges: Where most of our 
patients need our advice and medical skills, drug users need less advice and more listening, less 
medical knowledge and more caring. Where most of our patients have problems that we fix with 
drugs, for them, the drugs are the problem. When most of our patients come to us for our expertise, 
with drug using patients, they are the experts: they use a language we don’t understand, doses of 
drugs that terrify us, and come from lives that most of us will have little comprehension of. And 
when most of our patients are terrified of dying, most drug users seem terrified of living. 
 
Written by Gordon R Morse for SMMGP.  The views expressed by the author of this article are his personal 
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SMMGP Clinical Update 
The highlights of this month’s Clinical Update are: 
 
• Respiratory health screening for opiate misusers in a specialist community clinic: a 
mixed-methods pilot study. 
• A screening study to determine the prevalence of airway disease in heroin smokers.  
• Severe and fatal pharmaceutical poisoning in young children in the UK.  
• ‘‘You can never work with addictions in isolation’’: Addressing intimate partner violence 
perpetration by men in substance misuse treatment. 
• Medical professionals’ perspectives on prescribed and over-the-counter medicines 
containing codeine: a cross-sectional study.  
 
Euan Lawson – who has been writing our popular Clinical Updates for a long time - is standing 
down with this December 2016 update. We wish to express our sincere thanks to Euan for sharing 
his passion and expertise with us over the years, and we wish him well in his future endeavours.  




Respiratory health screening for opiate misusers in a specialist community clinic: a mixed-
methods pilot study, with integrated staff and service user feedback. Mitchell CA, Pitt A, Hulin 
J, et al. BMJ Open 2016;6:e012823 
 
This paper was based in a single community substance misuse clinic in England. They recruited 36 
participants and documented the respiratory health of participants using spirometry, a health-related 
quality of life questionnaire, the asthma control test, and other asthma and chronic obstructive 
airways disease (COPD) questionnaires. 
 
Out of 36 participants, 34 reported that they had smoked heroin. They had eight participants who 
were diagnosed with asthma and scored 13 on the asthma control test (suggesting poorly controlled 
asthma). There were a further 28 participants who did not have any respiratory diagnosis and out of 
these 79% scored under 18 on the Lung Function Questionnaire which suggests symptoms 
associated with the development of COPD. Spirometry showed that 14% of the participants had 
FEV1/FVC ratios that were consistent with obstructive airways disease. There was positive 
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A screening study to determine the prevalence of airway disease in heroin smokers. 
Lewis-Burke N, Vlies B, Wooding O, L Davies & Walker PP. COPD: Journal of Chronic Obstructive 
Pulmonary Disease 2016;13:3, 333-338  
 
This was a UK-based study where they aimed to determine the COPD prevalence in two local 
community drug services. They recruited 129 subjects and 107 were heroin smokers. They 
collected basic demographic details, smoking history information, and details of symptoms including 
MRC dyspnoea scores. They also completed a COPD assessment tool and performed spirometry. 
 
The result showed that 30 heroin smokers were identified as having COPD - giving an overall 
prevalence in this sample of 28%. Breathlessness and wheeze were more common in subjects with 
COPD but symptoms were common in all heroin smokers. They also noted that MRC dyspnoea 
scores were higher in those with COPD and health status was lower. Only four of the subjects 
(11%) had previously been diagnosed with COPD and only 16 (53%) had received any inhaled 
medication. The asthma prevalence was very high at 33% and, like the people with COPD, they 
were similarly and significantly undertreated. 
 
Commentary: It is crucial to remember that if somebody has any symptoms at all then further 
evaluation and management is normal clinical practice and doesn’t need to be justified in the same 
way as a screening process. Just because their care has been appalling doesn’t now make it 
screening. That’s important because there is a risk that one might look at these studies and be 
uncertain about whether to do such measures as spirometry and assessment of respiratory health. 
They absolutely should be going on. 
 
And note the finding in the Lewis-Burke study that symptoms were common in heroin smokers. We 
can have a debate about whether we should screen those who are asymptomatic but, for those in 
current clinical practice, don’t delay. Get a handheld spirometer, ask the questions and start finding 
these people and having these conversations to manage their health.  
 
Severe and fatal pharmaceutical poisoning in young children in the UK. Anderson M, 
Hawkins L, Eddleston M, Thompson JP, Vale JA, Thomas SH. Arch Dis Child 2016, May 16. 
 
This study was an analysis of national data sets that contained information relating to severe and 
fatal poisoning in children in the UK. They found that between 2001 and 2013 there were 28 
children aged under four years who died due to accidental poisoning as a result of a pharmaceutical 
product in England and Wales. Methadone was the responsible drug in 16 (57%) cases. They also 
found that a further 201 children aged four years and under were admitted to the paediatric 
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responsible drug was found in just 115 children and the most common drugs were benzodiazepines 
(22/115, 19%) and methadone (20/115, 17%). 
 
Commentary: This paper in the Archives of Disease in Childhood is not specifically related to 
substance misuse but it is the findings that are so pertinent. Like any research paper the language 
tends to be neutral but referring to registered deaths as ‘cases’ can’t gloss over the highly 
uncomfortable finding in this paper that 16 children died as a consequence of methadone poisoning. 
And that methadone will almost certainly (though the paper doesn’t have this level of detail) have 
been prescribed for people as part of opioid substitution therapy. Each of these deaths is an 
appalling tragedy. 
 
We provide safe boxes in our services and all the services that I’ve worked in always have provided 
these boxes. This is the absolute minimum we should be doing but I also think it is important that we 
don’t simply pay lip service to this, that we make it an active part of our consultations with people 
who are prescribed OST and have these drugs at home. We need to take every opportunity to warn 
people and to highlight, again and again, the devastating consequences to children of any ingestion 
at all of substances such as methadone. Resolve now to do more in each and every consultation. 
 
‘‘You can never work with addictions in isolation’’: Addressing intimate partner 
violence perpetration by men in substance misuse treatment. Radcliffe P, Gilchrist G. Int 
J Drug Policy 2016 Oct;36:130-140 
 
This paper reported on a discourse analysis of drugs and alcohol policy documents over the period 
1998-2015 that examined how English drug and alcohol policy has addressed intimate partner 
violence (IPV) among substance misusers. They also completed interviews with 20 stakeholders 
and analysed these interviews thematically. 
 
Their results showed that the way in which policy "frames" IPV perpetration among drug and alcohol 
misuse has implications for how that service provision will then occur. They noted that in recent 
years IPV has been given a raised profile due to its implications in child safeguarding. The authors 
draw attention to how the ACMD produced the Hidden Harm report in 2003 which drew attention to 
the estimated 250,000-350,000 children of drug misusing parents and the risks to which they were 
exposed. The concern then was about the risk of children witnessing intimate partner violence and 
this seemed to mark one of the first occasions when substance misuse, child abuse and neglect 
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The in-depth telephone interviews involved five national policymakers and 15 practitioners in the 
substance misuse sectors in London and south-east England. The overall results suggested that 
practitioners were not particularly knowledgeable about IPV perpetration amongst substance 
misusers. Overall, the identification of IPV perpetration was generally reported to be opportunistic. 
Even in areas where there is a MARAC (multi agency risk assessment conference) there were often 
occasions when victims were slow to be referred. 
 
More obviously, it was clear there were very few examples of perpetrator programs that the 
treatment providers could use to get help for perpetrators and that practitioners only had a very 
vague understanding of the possibility of finding routes to help perpetrators.  
 
Commentary: This is a detailed paper and the conclusions are not always straightforward. Most 
importantly for me, it challenged my views on those who perpetrate the violence. For example, the 
report offers views on Responsible Disinhibition Theory – one that it is often used as a post hoc 
justification or ‘excuse’ that covers up individual responsibility for violence that, arguably, would take 
place anyway. It is clear that male power and control is a central driver for IPV perpetration. I’m 
inclined to think back to all the men with whom I’ve had consultations who were guilty of intimate 
partner violence. And, yet, I’ve barely raised it, hardly talked about it. We tend to reserve our 
consultations for those who are victims, not the aggressors. I’m not alone in this and the paper was 
clear that there simply do not seem to be services for perpetrators.  
 
Clearly IPV perpetration has a complex set of factors when we deal with populations who are 
vulnerable, socially disadvantaged and who may well themselves have been abused in the past or 
are still abused now. There was an inherent paradox uncovered in the paper with some staff who 
perceived they did not always have the skills necessary to ask questions about IPV perpetration but, 
on the other hand, the treatment aspirations of people who enter services often include the desire to 
improve their relationships.  
 
One practitioner put it thus: "you can never work with addictions in isolation". If you don't feel 
confident in managing perpetrators of IPV then perhaps this is an area, as suggested by NICE in 
their 2014 guidelines for domestic abuse, that you should be seeking to develop for yourself and 
your organisation.  
 
Medical professionals’ perspectives on prescribed and over-the-counter medicines 
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This study was a cross-sectional design using a questionnaire to ask 300 prescribing professionals 
working in primary care settings about their perspective on prescribed codeine use, their ability to 
identify dependence, and the options for treatment in the UK. 
 
The participants indicated that they regularly reviewed patients who were prescribed codeine, 
understood the risk of dependence and recognised the potential for codeine to be used 
recreationally. However, over half of the participants felt that the patients were unaware of the 
potential adverse health consequences of using high doses of combination codeine medications. 
They also noted that a quarter of the participants had found patients resented being asked about 
medicines containing codeine.  
 
There were 40% of participants who thought it was difficult to identify problematic use of codeine 
unless they were informed by the patient and they did not feel confident in identifying codeine 
dependence. And, less than 45% of the participants agreed that codeine dependency could be 
managed effectively in general practice. The most popular method of managing was a slow gradual 
withdrawal of the codeine-based products with a strong emphasis on education and counselling 
options. 
 
Commentary: This was the first study which has examined medical professionals’ perceptions of 
medicines containing codeine across UK. One of the things I noted from the demographic details 
was that just under 30% of the professionals interviewed had had specialist training in substance 
misuse. That’s woeful. Overall, most of the people interviewed were general practitioners (79%) but 
they did also interview some independent prescribers and specialists in family medicine. No pain 
specialists responded to the invitation to participate in the research. The lack of specialist training in 
substance misuse indicates there is still a significant gap between education and practitioners.  
 
Managing opioid misuse and dependence is a huge challenge. I’d argue that despite the views of 
many people that it can’t be managed in general practice, the problem is that it can’t be managed 
anywhere just yet. No one has the resources and there is little in the way of existing systems.  
 
Services need to be developed that will address the wider medical concerns in those with 
dependence to prescribed opioids. General practice is well placed to manage the holistic needs of 
this group but, as ever, it will need resources and those involved will need to develop their skills. 
That’s quite a challenge when so many other problems are competing for time and money.  
 
SMMGP is part of the Opioid Painkiller Dependence Alliance, for more information about the aims of 
the Alliance, see www.opda.org.uk  
